Infectious Encephalitis: Clinical Trials

27 trials for Infectious Encephalitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

27 completed. 27 Phase 2, 3 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 227Completed 27
Phase 33Completed 3
Phase 11Completed 1

Follow Infectious Encephalitis: new trials by email Literature Review of Infectious Encephalitis trials Research Report on Infectious Encephalitis

Trials (filtered) newest first · largest first

All 27 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
GBP560-A, GBP560-B, IXIARO - Japanese Encephalitis Virus Disease
Phase 1 / Phase 2CompletedSK Bioscience Co., Ltd.1612025-02-242026-09-11
Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age
JEVAX, JECEVAX - Japanese Encephalitis
Phase 2CompletedNational Institute of Hygiene and Epidemiology, Vietnam2202017-06-022018-09-17
Safety and Immunogenicity of JECEVAX in Young Children
JEVAX, JECEVAX-1, JECEVAX-0.8 - Japanese Encephalitis
Phase 2CompletedNational Institute of Hygiene and Epidemiology, Vietnam2002015-04-012016-06-28
New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
FSME-immune - Tick-borne Encephalitis
Phase 2 / Phase 3CompletedSormland County Council, Sweden2502015-01-012021-02-10
Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients
TBE virus vaccine - Tick Borne Encephalitis
Phase 2CompletedMedical University of Vienna342014-07-012022-02-03
The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans
Japanese Encephalitis vaccine, Yellow Fever vaccine - Yellow Fever, Encephalitis, Japanese
Phase 2CompletedSingapore General Hospital842013-10-012016-04-20
Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
FSME-immune - Tick-borne Encephalitis
Phase 2 / Phase 3CompletedSormland County Council, Sweden2002011-09-012015-11-18
Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis
Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)] - Japanese Encephalitis
Phase 2CompletedUniversity of Liverpool222009-05-012013-05-21
Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults
ChimeriVax-WN02 vaccine, Placebo - West Nile Fever
Phase 2CompletedSanofi Pasteur, a Sanofi Company4792008-10-012015-04-03
Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine
Inactivated, Dried, TSI-GSD 104, EEE - Eastern Equine Encephalitis
Phase 2CompletedU.S. Army Medical Research and Development Command1382008-06-032019-09-24
Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine
Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104 - Eastern Equine Encephalitis
Phase 2CompletedU.S. Army Medical Research and Development Command1382008-06-032020-03-17
Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children
Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28), Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28) - Japanese Encephalitis, Hepatitis A
Phase 2CompletedSanofi Pasteur, a Sanofi Company3002008-03-012014-10-02
Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age
ChimeriVax™-JE, Japanese Encephalitis Inactivated Mouse Brain Vaccine - Japanese Encephalitis
Phase 2CompletedSanofi962007-01-012012-08-27
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose - West Nile Fever
Phase 2CompletedSanofi Pasteur, a Sanofi Company2082005-12-012016-04-14
A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX
ChimeriVax™-JE vaccine, JE-VAX® vaccine - Japanese Encephalitis
Phase 2CompletedSanofi602005-05-012012-08-20
Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)
Enfuvirtide, Tenofovir-Emtricitabine - Leukoencephalopathy, Progressive Multifocal, HIV Infections
Phase 2CompletedFrench National Agency for Research on AIDS and Viral Hepatitis302005-04-012026-04-02
Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine
Live attenuated Japanese encephalitis virus, ChimeriVax™ diluent (Placebo) - Japanese Encephalitis
Phase 2CompletedSanofi1282004-11-012012-12-05
Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)
Live attenuated Japanese encephalitis virus; Yellow fever virus, Yellow fever virus; Live attenuated Japanese encephalitis virus - Japanese Encephalitis, Yellow Fever
Phase 2CompletedSanofi1082004-07-012012-09-20
A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults
Live attenuated Japanese encephalitis virus, then ChimeriVax diluent, ChimeriVax diluent, then Live attenuated Japanese encephalitis virus - Encephalitis, Japanese Encephalitis
Phase 2CompletedSanofi2022003-04-012012-07-16
Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers
Three 1 mL doses of Rabies vaccine and two JE vaccine, Three 0.5 mL doses of Rabies vaccine and two JE vaccine, Three 0.1mL doses of Rabies Vaccine and two JE vaccine - Rabies, Japanese Encephalitis
Phase 2CompletedNovartis2002002-08-012008-06-10

Showing 20 of 27. Sign in to see all of them.

Narrower conditions

Encephalitis, Japanese (12)  ·  Encephalitis, Tick-Borne (8)  ·  HIV Infections (3)  ·  Leukoencephalopathy, Progressive Multifocal (3)  ·  Encephalomyelitis, Eastern Equine (2)  ·  West Nile Fever (2)  ·  Yellow Fever (2)  ·  AIDS-Related Opportunistic Infections (1)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Encephalitis (1)  ·  Hepatitis A (1)  ·  Rabies (1)  ·  Viremia (1)

Broader conditions

Brain Diseases (27)  ·  Central Nervous System Diseases (27)  ·  Central Nervous System Infections (27)  ·  Central Nervous System Viral Diseases (27)  ·  Encephalitis, Viral (27)  ·  Infections (27)  ·  Nervous System Diseases (27)  ·  Neuroinflammatory Diseases (27)  ·  RNA Virus Infections (27)  ·  Virus Diseases (27)  ·  Encephalitis (26)  ·  Arbovirus Infections (24)  ·  Encephalitis, Arbovirus (24)  ·  Vector Borne Diseases (24)

Interventions

Vaccines (3)  ·  Desiccation (2)  ·  Japanese Encephalitis Vaccines (2)  ·  Saline Solution (2)  ·  Cytarabine (1)  ·  Didanosine (1)  ·  Enfuvirtide (1)  ·  FSME-IMMUN vaccine (1)  ·  Filgrastim (1)  ·  Hepatitis A Vaccines (1)  ·  Immunoglobulins, Intravenous (1)  ·  Topotecan (1)  ·  Yellow Fever Vaccine (1)  ·  Zalcitabine (1)  ·  Zidovudine (1)

Sponsors

Pfizer (5)  ·  Sanofi (5)  ·  Sanofi Pasteur, a Sanofi Company (3)  ·  National Institute of Hygiene and Epidemiology, Vietnam (2)  ·  Sormland County Council, Sweden (2)  ·  U.S. Army Medical Research and Development Command (2)  ·  French National Agency for Research on AIDS and Viral Hepatitis (1)  ·  Medical University of Vienna (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Novartis (1)  ·  SK Bioscience Co., Ltd. (1)  ·  Singapore General Hospital (1)  ·  SmithKline Beecham (1)  ·  University of Liverpool (1)

Countries

United States (7)  ·  Australia (4)  ·  Austria (4)  ·  Germany (4)  ·  Finland (2)  ·  Sweden (2)  ·  Thailand (2)  ·  Vietnam (2)  ·  France (1)  ·  India (1)  ·  Nepal (1)  ·  New Zealand (1)  ·  Singapore (1)

Top investigators

Robert Rivard, MD (2)  ·  Thiem D Vu, MD., PhD. (2)  ·  Ulrich Behre, MD (2)  ·  Ajit Rayamajhi, MBBS, MD (1)  ·  Anand Dubey, M.D (1)  ·  Atul Shanker, Dr. (1)  ·  Bakul B. Javadekar, M.D. (1)  ·  Christina Forstner, MD (1)  ·  Dominique Costagliola (1)  ·  Hall C (1)  ·  Jacques Gasnault, MD (1)  ·  Jenny Low Guek Hong (1)

Results publications

PMID 20856164, PMID 20864814, PMID 21148499, PMID 21150279, PMID 21738597, PMID 25872531, PMID 25886645, PMID 27686833, PMID 27815383, PMID 32728481, PMID 33899755, PMID 34452033, PMID 35101266

NIH funding

2005 (1)